JAK inhibitors for the treatment of vitiligo
Shintaro Inoue, Tamio Suzuki, Shigetoshi Sano, Ichiro Katayama
Abstract
Vitiligo is an autoimmune disease involving melanocyte-targeting T cells initiated by environmental and genetic factors. Steroids and tacrolimus have been used as topical treatments. Recently, novel topical agents targeting Janus kinase (JAK), a family of tyrosine kinases that regulates cytokine signaling, have emerged. Ruxolitinib is the first approved in vitiligo therapy. Furthermore, ritlecitinib is currently under clinical trials for oral treatment of active vitiligo. In this review, we discuss the possibility of topical JAK inhibitors as promising options for the treatment of vitiligo with regard to their mechanism of action, efficacy and safety.
Topics & Concepts
VitiligoJanus kinaseMedicineRuxolitinibDermatologyTacrolimusClinical trialTyrosine kinasePharmacologyImmunologyCytokineInternal medicineReceptorTransplantationBone marrowMyelofibrosismelanin and skin pigmentationMast cells and histamineAtherosclerosis and Cardiovascular Diseases